Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Lundbeck Acquires Chelsea As Industry Awaits Possible AstraZeneca, Allergan Buyouts

Executive Summary

Merck sells off its consumer business to Bayer AG in a deal in which the two companies also will co-develop and co-commercialize sGC modulator drugs. Lundbeck buys out Chelsea and its recently approved dizziness drug Northera.

You may also be interested in...



Danish Lundbeck’s Brexpiprazole Could Reach U.S. Market In 2015

But the CNS disease specialist also expects the continuing loss of marketing exclusivity on key products and product launch costs to hold back revenue growth and profits in 2015 that will not be fully compensated by sales from multiple new product launches around the world.

Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split

A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.

Amgen Enters Cancer Biologics Deal With Oxford Genome Sciences

Collaboration is the second in recent months to involve Amgen’s XenoMouse human monoclonal antibody generating technology.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel